# Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

> **NCT04018027** · PHASE2 · COMPLETED · sponsor: **Cara Therapeutics, Inc.** · enrollment: 401 (actual)

## Conditions studied

- Pruritus
- Atopic Dermatitis

## Interventions

- **DRUG:** difelikefalin 0.25 mg
- **DRUG:** difelikefalin 0.5 mg
- **DRUG:** difelikefalin 1.0 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04018027
- **Lead sponsor:** Cara Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-29
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 401 (ACTUAL)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04018027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04018027, "Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04018027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*